COVID-19 impact on screening test volume through the National Breast and Cervical Cancer early detection program, January–June 2020, in the United States

DeGroff, Amy; Miller, Jacqueline W.; Sharma, Krishna P.; Sun, Juzhong; Helsel, William; Kammerer, William; Rockwell, Tanner; Sheu, Amy; Melillo, Stephanie; Uhd, Justin; Kenney, Kristy; Wong, Faye L.; Saraiya, Mona; Richardson, Lisa C.

doi:10.1016/j.ypmed.2021.106559

Cited by 116 publications

(159 citation statements)

References 16 publications

Supporting

Mentioning

119

Contrasting

Order By: Relevance

“…Notably, substantially fewer cancers were diagnosed in Asian, Hispanic, and non-Hispanic Black women compared to non-Hispanic White women. These results are consistent with prior studies which have found racial/ethnic disparities in breast cancer screening and diagnostic imaging use during the pandemic ( 6 , 22 , 23 ). Greater pandemic-related delays have also been observed among Asian and Hispanic individuals for imaging in general ( 15 ) and for individuals residing in communities with high levels of poverty ( 15 , 24 ).…”

Section: Discussionsupporting

confidence: 92%

Breast Biopsy Recommendations and Breast Cancers Diagnosed during the COVID-19 Pandemic

et al. 2022

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

Breast Biopsy Recommendations and Breast Cancers Diagnosed during the COVID-19 Pandemic

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In one such model, it was predicted that delays in cancer screening and treatment for breast and colorectal cancer would result in approximately 10,000 excess deaths (~1% increase in expected deaths from these cancers) [ 1 ]. Our findings were also consistent with other studies that demonstrated a substantial drop-off from March through June 2020, followed by a rapid increase in cancer screenings to rates similar to, or better than, those seen before the pandemic [ 3 , 4 , 5 , 8 , 9 , 10 , 11 , 12 ]. Other studies looking at the recovery period demonstrated a similar return to prior screening rates without a catch-up period to close the gap in missed screenings, particularly in colorectal cancer screening [ 8 , 9 , 12 ].…”

Section: Discussionsupporting

confidence: 92%

“…One of the unique aspects of this study was the method of calculating a SLR to determine the relative magnitude of change in screening. This contrasts with the many other studies describing cancer screening losses that focused on absolute screening deficits and percentage changes during the first peak of the pandemic and subsequent recovery periods [ 8 , 9 , 10 , 11 ]. One advantage of our methodology was in using the SLR tool to compare sex, race, and ethnicity subgroups within the study to identify and measure subtle screening disparities.…”

Section: Discussionmentioning

confidence: 72%

Impact of the COVID-19 Pandemic on Colorectal and Prostate Cancer Screening in a Large U.S. Health System

et al. 2022

View full text Add to dashboard Cite

During the first year of the coronavirus disease 2019 (COVID-19) pandemic, prevention measures included quarantining and facility closures. Because cancer screening is dependent on interventions in facilities, the extent of the COVID-19 impact on screening was questioned. A claims registry from a large health system was queried for colorectal and prostate cancer screening. A screening gap and screening loss ratio were calculated by comparing 2020 screening to historical reference years. All cancer screenings decreased in the first four months of the pandemic. Colorectal cancer screening returned to baseline in the latter six months of 2020. Prostate cancer screening exceeded baseline in the latter six months, but with a lesser gain than previous years. Populations disproportionately affected by decreased cancer screening included men and black people. To catch-up after the initial deficit in screening, it is estimated that the rate of colorectal cancer screening needs to increase by 50%.

show abstract

“…The decrease in colon, rectal, and anus cancer may be linked to the suspension of the screening program in the province of Girona between March and August 2020. In fact, several studies have quantified the reduction of screenings, both breast and colorectal, at between 40% and 80% from 2019 to 2020, depending on the time of interruption [ 17 , 31 , 32 , 33 , 34 , 35 ]. In this regard, it is surprising not to see a reduction in the diagnosis of breast cancer, although the loss of screening tests could be offset by the increase in chest examinations due to COVID-19, as some studies have noted [ 16 , 30 , 36 ].…”

Section: Discussionmentioning

confidence: 99%

Differences in the Impact of COVID-19 on Pathology Laboratories and Cancer Diagnosis in Girona

Sanvisens

Puigdemont

Rubió‐Casadevall

et al. 2021

IJERPH

View full text Add to dashboard Cite

Introduction: The recent COVID-19 pandemic has compromised socio-health care, with consequences for the diagnosis and follow-up of other pathologies. The aim of this study was to evaluate the impact of COVID-19 on cancer diagnosis in Girona, Spain. Methodology: Observational study of samples received in two pathology laboratories during 2019–2020 (tertiary hospital in Girona and county hospital in Figueres). Date, sample type, and location and morphology were available. Samples were recoded to determine malignancy and grouped by location. Comparisons were made by calendar year and period of exposure to COVID-19. Results: 102,360 samples were included: 80,517 from Girona and 21,843 from Figueres. The reduction in activity in the pathology laboratories in 2020 compared to the previous year was 25.4% in Girona and 27.5% in Figueres. The reduction in cancer diagnoses in 2020 compared to 2019 was 6.8% in Girona and 21% in Figueres. In both laboratories, a decrease was observed in the diagnoses of neoplasms of the lip, oral cavity and pharynx, larynx, colon, rectum and anus, kidney and urinary system, melanoma, and central nervous system. A statistically significant higher probability of a sample received in the pathology laboratory displaying malignancy during COVID-19 was found (Girona: OR = 1.28, 95% CI: 1.23–1.34; Figueres: OR = 1.10, 95% CI: 1.01–1.20) with respect to the COVID-19-free period. Conclusions: The COVID-19 pandemic has resulted in a reduction in cancer diagnoses by pathology departments that varies according to tumor location and type of hospital. Despite this, the optimization of care resources and the recovery effort have partially reduced the impact of the pandemic in certain neoplasms.

show abstract

COVID-19 impact on screening test volume through the National Breast and Cervical Cancer early detection program, January–June 2020, in the United States

Cited by 116 publications

References 16 publications

Breast Biopsy Recommendations and Breast Cancers Diagnosed during the COVID-19 Pandemic

Breast Biopsy Recommendations and Breast Cancers Diagnosed during the COVID-19 Pandemic

Impact of the COVID-19 Pandemic on Colorectal and Prostate Cancer Screening in a Large U.S. Health System

Differences in the Impact of COVID-19 on Pathology Laboratories and Cancer Diagnosis in Girona

Contact Info

Product

Resources

About